Skip Navigation Links.
Collapse <span class="m110 colortj mt20 fontw700">Volume 12 (2024)</span>Volume 12 (2024)
Collapse <span class="m110 colortj mt20 fontw700">Volume 11 (2023)</span>Volume 11 (2023)
Collapse <span class="m110 colortj mt20 fontw700">Volume 10 (2022)</span>Volume 10 (2022)
Collapse <span class="m110 colortj mt20 fontw700">Volume 9 (2021)</span>Volume 9 (2021)
Collapse <span class="m110 colortj mt20 fontw700">Volume 8 (2020)</span>Volume 8 (2020)
Collapse <span class="m110 colortj mt20 fontw700">Volume 7 (2019)</span>Volume 7 (2019)
Collapse <span class="m110 colortj mt20 fontw700">Volume 6 (2018)</span>Volume 6 (2018)
Collapse <span class="m110 colortj mt20 fontw700">Volume 5 (2017)</span>Volume 5 (2017)
Collapse <span class="m110 colortj mt20 fontw700">Volume 4 (2016)</span>Volume 4 (2016)
Collapse <span class="m110 colortj mt20 fontw700">Volume 3 (2015)</span>Volume 3 (2015)
Collapse <span class="m110 colortj mt20 fontw700">Volume 2 (2014)</span>Volume 2 (2014)
Collapse <span class="m110 colortj mt20 fontw700">Volume 1 (2013)</span>Volume 1 (2013)
American Journal of Medical Case Reports. 2015, 3(6), 174-176
DOI: 10.12691/AJMCR-3-6-7
Case Report

HIT BY HEPARIN: A Rare Case of Late Onset Heparin Induced Thrombocytopenia

HAMZA HASHMI MD1, and UMAYR AZIMI MD1

1Grand Rapids Medical Education Partners

Pub. Date: May 19, 2015

Cite this paper

HAMZA HASHMI MD and UMAYR AZIMI MD. HIT BY HEPARIN: A Rare Case of Late Onset Heparin Induced Thrombocytopenia. American Journal of Medical Case Reports. 2015; 3(6):174-176. doi: 10.12691/AJMCR-3-6-7

Abstract

Heparin induced thrombocytopenia is a rare complication of heparin therapy that usually occurs within initial 5 to 10 days of heparin exposure. We present a rare case of delayed onset heparin induced thrombocytopenia that occurred one week after cessation.

Keywords

heparin induced thrombocytopenia, argatroban, coronary artery bypass grafting, serotonin release assay

Copyright

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References

[1]  Warkentin TE. Think of HIT. Hematology Am Soc Hematol Educ Program 2006:408-414.
 
[2]  Alving BM. How I treat heparin-induced thrombocytopenia and thrombosis. Blood2003; 101(1):31-37.
 
[3]  Warkentin TE. Clinical presentation of heparin-induced thrombocytopenia. Semin Hematol 1998;35 4 suppl:9-16.
 
[4]  Crowther MA, Cook DJ, Albert M, et al. The 4Ts scoring system for heparin-induced thrombocytopenia in medical-surgical intensive care unit patients. J Crit Care2010;25(2):287-293.
 
[5]  Denys B, Stove V, Philippe J, Devreese K. A clinical-laboratory approach contributing to a rapid and reliable diagnosis of heparin-induced thrombocytopenia. Thromb Res2008;123(1):137-145.
 
[6]  Lewis BE, Aranda C, Lewis M, Hoppensteadt D, Walenga JM, Fareed J. Unlike heparins newer oral anticoagulants do not interact with HIT antibodies and maybe useful in the long-term anticoagulant management of heparin compromised patients [abstracts]. Am Soc Hematol Educ Program 2011; 118(21).
 
[7]  Potzsch B, Klovekorn WP, Madlener K. Use of heparin during cardiopulmonary bypass in patients with a history of heparin-induced thrombocytopenia. N Engl J Med2000; 343(7):515.